Tags

Type your tag names separated by a space and hit enter

Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.
Am J Health Syst Pharm 2015; 72(12):1026-35AJ

Abstract

PURPOSE

Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented.

METHODS

In a single-center open-label study, selected adults hospitalized for asthma or COPD exacerbations over a 21-month period were randomly assigned to receive levalbuterol 1.25 mg three times daily (n = 55) or albuterol 2.5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted. Study outcomes included scheduled and rescue nebulizations, total treatment costs, hospital length of stay, and change in heart rate from baseline.

RESULTS

The numbers of scheduled nebulizations were similar in the levalbuterol and albuterol groups (mean ± S.D., 19.6 ± 13.4 versus 20.7 ± 14.4; p = 0.692), as were the numbers of rescue nebulizations (mean ± S.D., 0.7 ± 1.4 versus 0.8 ± 2.0; p = 0.849). The mean change from baseline in heart rate did not differ significantly between groups. Mean total treatment costs per patient were significantly greater with the use of levalbuterol ($8003, bootstrap 95% confidence interval [CI], $6628-$9379) versus albuterol ($5772, bootstrap 95% CI, $5051-$6494; p = 0.006). Hospital length of stay was significantly greater in the levalbuterol group (mean ± S.D., 8.5 ± 5.2 days versus 6.8 ± 3.6 days with albuterol use; p = 0.040).

CONCLUSION

Clinical outcomes were similar with the use of levalbuterol versus albuterol for exacerbations of COPD or asthma. On average, patients receiving levalbuterol had longer and more costly hospital stays.

Authors+Show Affiliations

Luigi Brunetti, Pharm.D., M.P.H., is Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, and Clinical Pharmacy Specialist, Internal Medicine, Robert Wood Johnson University Hospital-Somerset, Somerville, NJ. George Poiani, M.D., FACP, FCCP, is Attending Physician, Department of Medicine, Robert Wood Johnson University Hospital-Somerset, and Clinical Associate Professor, Division of Pulmonary/Critical Care Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ. Fatema Dhanaliwala, B.S.Pharm., is Pharmacy Supervisor, Department of Pharmacy, Robert Wood Johnson University Hospital-Somerset. Kristen Poppiti, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, Inova Fairfax Hospital, Falls Church, VA; at the time of writing, she was a Pharm.D. student in the Honors Research Program at Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Haenam Kang, B.S., is Graduate Student, College of Pharmacy; and Dong-Churl Suh, M.B.A., Ph.D., is Professor, College of Pharmacy, Chung-Ang University, Seoul, South Korea.Luigi Brunetti, Pharm.D., M.P.H., is Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, and Clinical Pharmacy Specialist, Internal Medicine, Robert Wood Johnson University Hospital-Somerset, Somerville, NJ. George Poiani, M.D., FACP, FCCP, is Attending Physician, Department of Medicine, Robert Wood Johnson University Hospital-Somerset, and Clinical Associate Professor, Division of Pulmonary/Critical Care Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ. Fatema Dhanaliwala, B.S.Pharm., is Pharmacy Supervisor, Department of Pharmacy, Robert Wood Johnson University Hospital-Somerset. Kristen Poppiti, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, Inova Fairfax Hospital, Falls Church, VA; at the time of writing, she was a Pharm.D. student in the Honors Research Program at Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Haenam Kang, B.S., is Graduate Student, College of Pharmacy; and Dong-Churl Suh, M.B.A., Ph.D., is Professor, College of Pharmacy, Chung-Ang University, Seoul, South Korea.Luigi Brunetti, Pharm.D., M.P.H., is Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, and Clinical Pharmacy Specialist, Internal Medicine, Robert Wood Johnson University Hospital-Somerset, Somerville, NJ. George Poiani, M.D., FACP, FCCP, is Attending Physician, Department of Medicine, Robert Wood Johnson University Hospital-Somerset, and Clinical Associate Professor, Division of Pulmonary/Critical Care Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ. Fatema Dhanaliwala, B.S.Pharm., is Pharmacy Supervisor, Department of Pharmacy, Robert Wood Johnson University Hospital-Somerset. Kristen Poppiti, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, Inova Fairfax Hospital, Falls Church, VA; at the time of writing, she was a Pharm.D. student in the Honors Research Program at Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Haenam Kang, B.S., is Graduate Student, College of Pharmacy; and Dong-Churl Suh, M.B.A., Ph.D., is Professor, College of Pharmacy, Chung-Ang University, Seoul, South Korea.Luigi Brunetti, Pharm.D., M.P.H., is Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, and Clinical Pharmacy Specialist, Internal Medicine, Robert Wood Johnson University Hospital-Somerset, Somerville, NJ. George Poiani, M.D., FACP, FCCP, is Attending Physician, Department of Medicine, Robert Wood Johnson University Hospital-Somerset, and Clinical Associate Professor, Division of Pulmonary/Critical Care Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ. Fatema Dhanaliwala, B.S.Pharm., is Pharmacy Supervisor, Department of Pharmacy, Robert Wood Johnson University Hospital-Somerset. Kristen Poppiti, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, Inova Fairfax Hospital, Falls Church, VA; at the time of writing, she was a Pharm.D. student in the Honors Research Program at Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Haenam Kang, B.S., is Graduate Student, College of Pharmacy; and Dong-Churl Suh, M.B.A., Ph.D., is Professor, College of Pharmacy, Chung-Ang University, Seoul, South Korea.Luigi Brunetti, Pharm.D., M.P.H., is Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, and Clinical Pharmacy Specialist, Internal Medicine, Robert Wood Johnson University Hospital-Somerset, Somerville, NJ. George Poiani, M.D., FACP, FCCP, is Attending Physician, Department of Medicine, Robert Wood Johnson University Hospital-Somerset, and Clinical Associate Professor, Division of Pulmonary/Critical Care Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ. Fatema Dhanaliwala, B.S.Pharm., is Pharmacy Supervisor, Department of Pharmacy, Robert Wood Johnson University Hospital-Somerset. Kristen Poppiti, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, Inova Fairfax Hospital, Falls Church, VA; at the time of writing, she was a Pharm.D. student in the Honors Research Program at Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Haenam Kang, B.S., is Graduate Student, College of Pharmacy; and Dong-Churl Suh, M.B.A., Ph.D., is Professor, College of Pharmacy, Chung-Ang University, Seoul, South Korea.Luigi Brunetti, Pharm.D., M.P.H., is Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, and Clinical Pharmacy Specialist, Internal Medicine, Robert Wood Johnson University Hospital-Somerset, Somerville, NJ. George Poiani, M.D., FACP, FCCP, is Attending Physician, Department of Medicine, Robert Wood Johnson University Hospital-Somerset, and Clinical Associate Professor, Division of Pulmonary/Critical Care Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ. Fatema Dhanaliwala, B.S.Pharm., is Pharmacy Supervisor, Department of Pharmacy, Robert Wood Johnson University Hospital-Somerset. Kristen Poppiti, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, Inova Fairfax Hospital, Falls Church, VA; at the time of writing, she was a Pharm.D. student in the Honors Research Program at Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey. Haenam Kang, B.S., is Graduate Student, College of Pharmacy; and Dong-Churl Suh, M.B.A., Ph.D., is Professor, College of Pharmacy, Chung-Ang University, Seoul, South Korea. dongsuh75@gmail.com.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26025994

Citation

Brunetti, Luigi, et al. "Clinical Outcomes and Treatment Cost Comparison of Levalbuterol Versus Albuterol in Hospitalized Adults With Chronic Obstructive Pulmonary Disease or Asthma." American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, vol. 72, no. 12, 2015, pp. 1026-35.
Brunetti L, Poiani G, Dhanaliwala F, et al. Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. Am J Health Syst Pharm. 2015;72(12):1026-35.
Brunetti, L., Poiani, G., Dhanaliwala, F., Poppiti, K., Kang, H., & Suh, D. C. (2015). Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 72(12), pp. 1026-35. doi:10.2146/ajhp140551.
Brunetti L, et al. Clinical Outcomes and Treatment Cost Comparison of Levalbuterol Versus Albuterol in Hospitalized Adults With Chronic Obstructive Pulmonary Disease or Asthma. Am J Health Syst Pharm. 2015 Jun 15;72(12):1026-35. PubMed PMID: 26025994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. AU - Brunetti,Luigi, AU - Poiani,George, AU - Dhanaliwala,Fatema, AU - Poppiti,Kristen, AU - Kang,Haenam, AU - Suh,Dong-Churl, PY - 2015/5/31/entrez PY - 2015/5/31/pubmed PY - 2016/2/26/medline SP - 1026 EP - 35 JF - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JO - Am J Health Syst Pharm VL - 72 IS - 12 N2 - PURPOSE: Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented. METHODS: In a single-center open-label study, selected adults hospitalized for asthma or COPD exacerbations over a 21-month period were randomly assigned to receive levalbuterol 1.25 mg three times daily (n = 55) or albuterol 2.5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted. Study outcomes included scheduled and rescue nebulizations, total treatment costs, hospital length of stay, and change in heart rate from baseline. RESULTS: The numbers of scheduled nebulizations were similar in the levalbuterol and albuterol groups (mean ± S.D., 19.6 ± 13.4 versus 20.7 ± 14.4; p = 0.692), as were the numbers of rescue nebulizations (mean ± S.D., 0.7 ± 1.4 versus 0.8 ± 2.0; p = 0.849). The mean change from baseline in heart rate did not differ significantly between groups. Mean total treatment costs per patient were significantly greater with the use of levalbuterol ($8003, bootstrap 95% confidence interval [CI], $6628-$9379) versus albuterol ($5772, bootstrap 95% CI, $5051-$6494; p = 0.006). Hospital length of stay was significantly greater in the levalbuterol group (mean ± S.D., 8.5 ± 5.2 days versus 6.8 ± 3.6 days with albuterol use; p = 0.040). CONCLUSION: Clinical outcomes were similar with the use of levalbuterol versus albuterol for exacerbations of COPD or asthma. On average, patients receiving levalbuterol had longer and more costly hospital stays. SN - 1535-2900 UR - https://www.unboundmedicine.com/medline/citation/26025994/Clinical_outcomes_and_treatment_cost_comparison_of_levalbuterol_versus_albuterol_in_hospitalized_adults_with_chronic_obstructive_pulmonary_disease_or_asthma_ L2 - https://academic.oup.com/ajhp/article-lookup/doi/10.2146/ajhp140551 DB - PRIME DP - Unbound Medicine ER -